- Home
- CNTA vs NVCR Comparison
CNTA vs NVCR Comparison
Compare CNTA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- NVCR
- Stock Information
- Founded
- CNTA 2020
- NVCR 2000
- Country
- CNTA United Kingdom
- NVCR Switzerland
- Employees
- CNTA N/A
- NVCR N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- NVCR Medical/Dental Instruments
- Sector
- CNTA Health Care
- NVCR Health Care
- Exchange
- CNTA Nasdaq
- NVCR Nasdaq
- Market Cap
- CNTA 2.2B
- NVCR 1.9B
- IPO Year
- CNTA 2021
- NVCR 2015
- Fundamental
- Price
- CNTA $12.30
- NVCR $15.58
- Analyst Decision
- CNTA Strong Buy
- NVCR Buy
- Analyst Count
- CNTA 9
- NVCR 6
- Target Price
- CNTA $25.63
- NVCR $34.17
- AVG Volume (30 Days)
- CNTA 1.2M
- NVCR 736.7K
- Earning Date
- CNTA 05-12-2025
- NVCR 04-24-2025
- Dividend Yield
- CNTA N/A
- NVCR N/A
- EPS Growth
- CNTA N/A
- NVCR N/A
- EPS
- CNTA N/A
- NVCR N/A
- Revenue
- CNTA N/A
- NVCR $605,220,000.00
- Revenue This Year
- CNTA N/A
- NVCR $3.14
- Revenue Next Year
- CNTA N/A
- NVCR $10.63
- P/E Ratio
- CNTA N/A
- NVCR N/A
- Revenue Growth
- CNTA N/A
- NVCR 18.82
- 52 Week Low
- CNTA $7.75
- NVCR $11.70
- 52 Week High
- CNTA $19.09
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- CNTA 40.90
- NVCR 34.24
- Support Level
- CNTA $11.50
- NVCR $15.49
- Resistance Level
- CNTA $12.82
- NVCR $17.06
- Average True Range (ATR)
- CNTA 1.21
- NVCR 1.06
- MACD
- CNTA 0.03
- NVCR -0.01
- Stochastic Oscillator
- CNTA 50.95
- NVCR 20.42
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.